Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 08, 2024

BUY
$0.73 - $2.73 $4,130 - $15,446
5,658 Added 23.59%
29,646 $69,000
Q4 2023

Feb 09, 2024

BUY
$0.38 - $0.91 $9,115 - $21,829
23,988 New
23,988 $21,000
Q2 2023

Aug 11, 2023

SELL
$2.49 - $20.59 $9,561 - $79,065
-3,840 Reduced 12.95%
25,806 $69,000
Q4 2022

Feb 07, 2023

SELL
$13.27 - $17.73 $81,875 - $109,394
-6,170 Reduced 17.23%
29,646 $475,000
Q2 2022

Aug 05, 2022

BUY
$7.94 - $12.96 $79 - $129
10 Added 0.03%
35,816 $378,000
Q2 2021

Aug 10, 2021

BUY
$18.57 - $35.68 $22,692 - $43,600
1,222 Added 3.53%
35,806 $954,000
Q1 2021

May 10, 2021

SELL
$31.0 - $55.72 $520,800 - $936,096
-16,800 Reduced 32.7%
34,584 $1.2 Million
Q4 2020

Feb 08, 2021

SELL
$37.09 - $48.97 $82,339 - $108,713
-2,220 Reduced 4.14%
51,384 $1.91 Million
Q3 2020

Nov 09, 2020

BUY
$40.47 - $45.5 $561,318 - $631,085
13,870 Added 34.91%
53,604 $2.2 Million
Q1 2020

May 05, 2020

SELL
$23.3 - $45.96 $143,667 - $283,389
-6,166 Reduced 13.43%
39,734 $1.38 Million
Q4 2019

Feb 03, 2020

BUY
$34.58 - $48.06 $191,434 - $266,060
5,536 Added 13.72%
45,900 $1.97 Million
Q2 2019

Aug 05, 2019

BUY
$35.13 - $55.53 $25,293 - $39,981
720 Added 1.82%
40,364 $1.82 Million
Q1 2019

May 03, 2019

BUY
$42.83 - $59.91 $5,139 - $7,189
120 Added 0.3%
39,644 $2.16 Million
Q4 2018

Feb 01, 2019

BUY
$37.97 - $60.16 $143,906 - $228,006
3,790 Added 10.61%
39,524 $1.83 Million
Q2 2018

Aug 06, 2018

BUY
$44.9 - $64.95 $103,270 - $149,385
2,300 Added 6.88%
35,734 $2.24 Million
Q1 2018

May 04, 2018

BUY
$45.35 - $61.65 $94,917 - $129,033
2,093 Added 6.68%
33,434 $1.55 Million
Q4 2017

Feb 01, 2018

BUY
$41.95 - $60.1 $138,015 - $197,729
3,290 Added 11.73%
31,341 $1.49 Million
Q3 2017

Oct 31, 2017

BUY
$33.4 - $53.9 $936,903 - $1.51 Million
28,051
28,051 $1.51 Million

Others Institutions Holding FGEN

About FIBROGEN INC


  • Ticker FGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,741,200
  • Market Cap $32.8M
  • Description
  • FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...
More about FGEN
Track This Portfolio

Track State Board Of Administration Of Florida Retirement System Portfolio

Follow State Board Of Administration Of Florida Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Board Of Administration Of Florida Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on State Board Of Administration Of Florida Retirement System with notifications on news.